Related references
Note: Only part of the references are listed.Sample size methods for evaluation of predictive biomarkers
Kevin K. Dobbin et al.
STATISTICS IN MEDICINE (2022)
Biomarker Discovery and Validation: Statistical Considerations
Fang-Shu Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Khalid El Bairi et al.
NPJ BREAST CANCER (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial
Oleg Gluz et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting
Laura Pizzuti et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration
David M. Kent et al.
ANNALS OF INTERNAL MEDICINE (2020)
The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement
David M. Kent et al.
ANNALS OF INTERNAL MEDICINE (2020)
IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer
Dinja T. Kruger et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A. Jo Chien et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy
Michail Ignatiadis et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
Matteo Lambertini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial
S. Hrebien et al.
ANNALS OF ONCOLOGY (2019)
Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES
Zsolt Szijgyarto et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer
Nicola J. Camp et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Saranya Chumsri et al.
CLINICAL CANCER RESEARCH (2019)
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
Melanie Janning et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial
Anne-Sophie Hamy et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Ivana Sestak et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer
Hitomi Mori et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy
Julian Puppe et al.
CLINICAL CANCER RESEARCH (2019)
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Sibylle Loibl et al.
CLINICAL CANCER RESEARCH (2019)
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
Ulrike Nitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
Sandra M. Swain et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
A population-based recurrence risk management study of patients with pT1 node-negative HER2+breast cancer: a National Clinical Database study
Makoto Kubo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse
Chidananda M. Siddappa et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial
J. M. S. Bartlett et al.
ANNALS OF ONCOLOGY (2019)
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+breast cancer
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2019)
G-protein-coupled estrogen receptor GPER-1 expression in hormone receptor-positive breast cancer is associated with poor benefit of tamoxifen
Tanja Ignatov et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
O. Nanni et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER plus breast cancer
Lutfi H. Alfarsi et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Glutamate dehydrogenase (GLUD1) expression in breast cancer
Madeleine L. Craze et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial
Karama Asleh et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
Saranya Chumsri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98
Kevin H. Kensler et al.
BREAST CANCER RESEARCH (2019)
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
Barbara Adamo et al.
BREAST CANCER RESEARCH (2019)
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial
Stephen K. L. Chia et al.
BREAST CANCER RESEARCH (2019)
Post hoc power analysis: is it an informative and meaningful analysis?
Yiran Zhang et al.
GENERAL PSYCHIATRY (2019)
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Andrea C. Tricco et al.
ANNALS OF INTERNAL MEDICINE (2018)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An Approach to Evaluating and Comparing Biomarkers for Patient Treatment Selection
Holly Janes et al.
INTERNATIONAL JOURNAL OF BIOSTATISTICS (2014)
Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation
Boris Freidlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
Mei-Yin C. Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Criteria for the use of omics-based predictors in clinical trials
Lisa M. McShane et al.
NATURE (2013)
Statistical Challenges in the Evaluation of Treatments for Small Patient Populations
Edward L. Korn et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
Douglas G. Altman et al.
BMC MEDICINE (2012)
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nicholas B. La Thangue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Evaluating the predictiveness of a continuous marker
Ying Huang et al.
BIOMETRICS (2007)
Why most published research findings are false
JPA Ioannidis
PLOS MEDICINE (2005)
Clinical trial designs for predictive marker validation in cancer treatment trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test
ST Brookes et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Share Paper
